Your browser is no longer supported. Please, upgrade your browser.
Settings
DRNA Dicerna Pharmaceuticals, Inc. daily Stock Chart
DRNA [NASD]
Dicerna Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own0.10% Shs Outstand68.74M Perf Week-3.31%
Market Cap922.49M Forward P/E- EPS next Y-0.84 Insider Trans-93.19% Shs Float62.40M Perf Month-8.83%
Income-93.00M PEG- EPS next Q-0.22 Inst Own88.60% Short Float6.34% Perf Quarter-13.03%
Sales6.10M P/S151.23 EPS this Y-27.30% Inst Trans17.75% Short Ratio6.73 Perf Half Y7.53%
Book/sh2.85 P/B4.71 EPS next Y41.70% ROA-74.40% Target Price22.42 Perf Year74.29%
Cash/sh2.62 P/C5.11 EPS next 5Y- ROE-90.80% 52W Range6.80 - 17.98 Perf YTD48.62%
Dividend- P/FCF- EPS past 5Y-22.30% ROI-59.90% 52W High-25.36% Beta2.38
Dividend %- Quick Ratio6.30 Sales past 5Y-20.20% Gross Margin- 52W Low97.35% ATR0.86
Employees44 Current Ratio6.30 Sales Q/Q225.90% Oper. Margin- RSI (14)46.95 Volatility7.26% 6.34%
OptionableYes Debt/Eq0.00 EPS Q/Q62.20% Profit Margin- Rel Volume0.45 Prev Close12.85
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume587.01K Price13.42
Recom1.80 SMA20-3.27% SMA50-2.04% SMA200-0.25% Volume266,306 Change4.44%
Nov-06-18Upgrade B. Riley FBR Neutral → Buy $13.50 → $21
Sep-13-18Initiated Citigroup Buy $27
Aug-15-18Upgrade H.C. Wainwright Neutral → Buy $21
Aug-09-18Reiterated Stifel Buy $18 → $20
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $10
Mar-23-18Downgrade H.C. Wainwright Buy → Neutral $12
Mar-09-18Initiated Chardan Capital Markets Neutral
Feb-05-18Initiated SunTrust Buy $13
Jan-16-18Initiated Evercore ISI Outperform $14
Nov-03-17Reiterated H.C. Wainwright Buy $6 → $10
May-23-17Resumed H.C. Wainwright Buy $5
Apr-10-17Reiterated H.C. Wainwright Buy $8 → $5
Jan-31-17Resumed Leerink Partners Mkt Perform
Dec-12-16Initiated H.C. Wainwright Buy $7
Aug-15-16Reiterated Chardan Capital Markets Neutral $4 → $3.50
Aug-08-16Reiterated Chardan Capital Markets Neutral $4 → $3.50
Jun-30-16Reiterated Stifel Buy $16 → $13
Jun-30-16Reiterated Chardan Capital Markets Neutral $5 → $4
May-10-16Reiterated Stifel Buy $20 → $16
Apr-05-16Initiated Chardan Capital Markets Neutral $5
Nov-30-18 07:45AM  Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-29-18 07:30AM  Dicerna to Participate in Citis 2018 Global Healthcare Conference Business Wire
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-09-18 08:00AM  Dicerna to Highlight Lead GalXC Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018 Business Wire
Nov-06-18 07:30AM  Dicerna to Participate in Upcoming Investor Conferences Business Wire +10.90%
01:25AM  Edited Transcript of DRNA earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-05-18 06:40PM  Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:36PM  Dicerna Pharmaceuticals: 3Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update Business Wire
Nov-01-18 09:55AM  3 Pharma Stocks to Make a Portfolio Feel Better Investopedia
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-30-18 07:30AM  Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018 Business Wire
Oct-29-18 09:31AM  Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal Benzinga
07:09AM  Dicerna's stock rockets after licensing, research collaboration with Eli Lilly MarketWatch
06:00AM  Lilly and Dicerna Announce RNAi Licensing and Research Collaboration PR Newswire
06:00AM  Eli Lilly makes bet on gene-silencing drug firm Dicerna Reuters
06:00AM  Drug giant Lilly backs Cambridge's Dicerna in $200M deal American City Business Journals
Oct-25-18 01:00PM  Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2) Business Wire +7.90%
Oct-24-18 11:28PM  Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript Motley Fool
04:41PM  Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue Investor's Business Daily
10:46AM  Alexion enters RNA gene-silencing field with $637M Dicerna deal American City Business Journals
07:49AM  Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance MarketWatch
06:30AM  Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases Business Wire
Oct-23-18 08:25AM  New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-05-18 12:54PM  Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018 Business Wire
Sep-24-18 07:30AM  Dicerna to Participate in Two Upcoming Investor Conferences Business Wire +5.50%
Sep-12-18 06:00PM  Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace
Sep-07-18 02:32PM  Here's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% Today Motley Fool +13.75%
11:00AM  3 Stocks to Watch as Immunotherapy Pushes Biotech Growth ACCESSWIRE
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 10:58PM  Dicerna Announces Pricing of Follow-On Public Offering of Common Stock Business Wire -18.11%
Sep-05-18 04:01PM  Dicerna Announces Proposed Follow-On Public Offering of Common Stock Business Wire
06:05AM  Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria Business Wire
Aug-29-18 08:10AM  Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott Fundamental Analysis, Key Performance Indications GlobeNewswire
07:30AM  Dicerna to Participate in Upcoming Investor Conferences Business Wire
Aug-16-18 06:00PM  Dicerna Strengthens Board of Directors with Two New Appointments Business Wire
Aug-14-18 01:30AM  Edited Transcript of DRNA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-18 10:20PM  Alnylam drug approval marks watershed moment for gene-silencing field American City Business Journals
Aug-08-18 07:15PM  Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:08PM  Dicerna Pharmaceuticals: 2Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update Business Wire
02:30PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:13AM  Earnings Outlook For Dicerna Pharmaceuticals Benzinga
Aug-01-18 07:30AM  Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018 Business Wire
Jul-25-18 08:20AM  Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
Jul-11-18 07:30AM  Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EU Business Wire
Jun-19-18 07:30AM  Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes Business Wire
Jun-18-18 07:20AM  Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks ACCESSWIRE
May-30-18 07:30AM  Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial Business Wire
May-29-18 07:30AM  Dicerna to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
07:10AM  Wired News Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R) ACCESSWIRE
May-18-18 07:55AM  Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR International, and Nordson with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-16-18 03:52AM  Edited Transcript of DRNA earnings conference call or presentation 14-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-14-18 04:16PM  Dicerna Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update Business Wire
12:30PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:43AM  Where Dicerna Pharmaceuticals Incs (NASDAQ:DRNA) Earnings Growth Stands Against Its Industry Simply Wall St.
May-07-18 07:30AM  Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018 Business Wire +5.07%
Apr-20-18 04:08PM  Why Dicerna Rocketed Higher Today Motley Fool +17.86%
02:20PM  Dicerna to pay $27M to settle Alnylam trade secrets lawsuit American City Business Journals
01:55PM  U.S. biotech companies Alnylam, Dicerna settle trade secrets case Reuters
01:03PM  UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case Reuters
12:13PM  Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam Business Wire
Apr-03-18 07:30AM  Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-28-18 03:09PM  Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation Benzinga -11.00%
Mar-23-18 08:25AM  Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-14-18 07:40AM  Wired News Alnylam Retains Global Rights for its Investigational RNAi Therapeutic Lumasiran ACCESSWIRE
Mar-09-18 04:16PM  Edited Transcript of DRNA earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
09:50AM  Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point Benzinga
07:30AM  Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium Business Wire
Mar-08-18 04:30PM  Dicerna Pharmaceuticals posts 4Q loss Associated Press
04:05PM  Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update Business Wire
01:00PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 07:30AM  Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire
Mar-01-18 12:16PM  [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna Barrons.com
07:30AM  Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018 Business Wire
Feb-06-18 07:30AM  Dicerna to Participate in Upcoming Investor Conferences Business Wire +7.49%
Jan-24-18 07:30AM  Analysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-23-18 07:30AM  Dicerna to Present at Noble Capital Markets NobleCon14 Business Wire +14.32%
Dec-28-17 08:44AM  Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher Zacks
Dec-21-17 07:58AM  [$$] Bain Makes Bank in Two Rebounding Biotechs Barrons.com +8.15%
Dec-14-17 01:14PM  ETFs with exposure to Dicerna Pharmaceuticals, Inc. : December 14, 2017 Capital Cube -6.76%
09:29AM  Dicerna Announces Pricing of Follow-On Public Offering of Common Stock Business Wire
07:45AM  With -20.9% EPS Drop, Should Dicerna Pharmaceuticals Incs (NASDAQ:DRNA) Recent Track Record Be A Cause Of Concern? Simply Wall St.
Dec-13-17 04:45PM  Dicerna Announces Proposed Public Offering of Common Stock Business Wire
Dec-07-17 07:30AM  Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria Business Wire
Nov-28-17 12:09PM  ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 28, 2017 Capital Cube -5.56%
Nov-21-17 07:30AM  Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference Business Wire
Nov-09-17 08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
Nov-08-17 05:57PM  ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 8, 2017 Capital Cube
07:30AM  Dicerna to Present at the Stifel 2017 Healthcare Conference Business Wire
07:06AM  Edited Transcript of DRNA earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 08:05AM  Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-02-17 06:27PM  Dicerna Pharmaceuticals posts 3Q loss Associated Press +28.19%
04:05PM  Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update Business Wire
12:20PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:30AM  Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH) Business Wire
Oct-26-17 07:30AM  Dicerna to Report Third Quarter 2017 Financial Results and Host Conference Call on November 2, 2017 Business Wire
Oct-16-17 07:30AM  Dicerna Files Clinical Trial Application for DCR-PHXC, the Companys Most Advanced GalXC Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH) Business Wire -5.02%
Sep-20-17 07:30AM  Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series Business Wire +18.21%
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; a license agreement with City of Hope; and a licensing and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Halak Brian KDirectorNov 06Sale13.19104,3281,376,51319,150Nov 06 04:16 PM
Halak Brian KDirectorNov 05Sale12.9839,901517,91519,922Nov 06 04:16 PM
Halak Brian KDirectorNov 02Sale13.47190,7712,569,68520,217Nov 06 04:16 PM
Halak Brian KDirectorNov 01Sale13.37189,5752,534,61821,629Nov 01 06:08 PM
Halak Brian KDirectorOct 31Sale13.60129,6291,762,95423,037Nov 01 06:08 PM
Halak Brian KDirectorOct 30Sale13.92245,0963,410,61923,996Nov 01 06:08 PM
Weissman James BChief Business OfficerSep 05Option Exercise3.422,3017,86926,781Sep 06 02:21 PM
Weissman James BChief Business OfficerSep 05Sale17.502,30140,26824,480Sep 06 02:21 PM
Weissman James BChief Business OfficerAug 17Option Exercise3.4214,68050,20624,480Aug 20 09:00 PM
LANGER DENNISDirectorAug 15Sale16.0023,810380,96047,978Aug 17 09:00 PM
LANGER DENNISDirectorAug 15Sale16.0014,531232,49629,064Aug 17 09:00 PM
Halak Brian KDirectorJun 07Option Exercise7.0021,197148,3793,490,070Jun 11 04:12 PM
Weissman James BChief Business OfficerMay 09Option Exercise3.4210,00034,20019,800May 11 09:00 PM
Brown Bob DChief Scientific OfficerMay 09Sale15.009,669145,0359,670May 11 09:00 PM
Weissman James BChief Business OfficerMay 09Sale15.0010,000150,0009,800May 11 09:00 PM
Weissman James BChief Business OfficerApr 20Sale13.008,965116,5459,800Apr 24 09:30 PM
Weissman James BChief Business OfficerMar 19Sale13.001,03513,45518,765Mar 21 09:30 PM
LANGER DENNISDirectorJan 26Option Exercise3.423601,23171,788Jan 30 09:30 PM
Bain Capital Life Sciences InvDirectorDec 18Buy7.00285,0001,995,000285,000Dec 19 04:52 PM